The effect of the COVID-19 pandemic on epistaxis and anaemia in patients with hereditary haemorrhagic telangiectasia (HHT) in central South Africa
Open Access
- 16 July 2025
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-13
Abstract
Background: Recurrent epistaxis, which frequently results in iron deficiency anaemia and impaired quality of life, is the most frequent complication of hereditary haemorrhagic telangiectasia (HHT). Specific data to guide rare disease management during a pandemic such as COVID-19 are lacking. Methods: To better define the impact of the COVID-19 pandemic on HHT, we conducted a retrospective and prospective observational descriptive review of HHT patients in central South Africa. Epistaxis severity scores (ESSs) and haemoglobin (Hb) levels before and after the start of the pandemic were compared. Variables that may have influenced epistaxis severity and anaemia were investigated, viz. (i) mask use, (ii) nasal versus oral swabs to test for SARS-CoV-2, (iii) COVID-19 disease and (iv) its management, (v) COVID-19 vaccines, and (vi) the social impact of the pandemic. Results: Twenty-four patients with confirmed HHT were included in the study. Subset analyses revealed a clinically significant change in ESSs (≥ 0.71 minimal important difference) and Hb levels (> 2.7% biologic variation) in 6/11 (54.6%) and 12/15 (80%) patients. While the median ESS improved in 2/11 (18.2%) patients, it worsened in 4/11 (36.4%) patients during the pandemic. However, the changes in the median ESS (2.25 pre-pandemic versus 2.5 during the pandemic; p = 0.38) and Hb level (9.5 g/dL pre-pandemic versus 10 g/dL during the pandemic; p = 0.38) for the study population were not statistically significant. Clinical and social variables that may influence epistaxis severity and anaemia were identified. Nasal swab testing for SARS-CoV-2 induced epistaxis in 9/12 (75%) cases and was noted as an important factor. Conclusion: The COVID-19 pandemic has had a clinically significant impact on epistaxis severity and anaemia in some individuals with HHT in central South Africa. Specific strategies are needed to optimise the management of HHT during the COVID-19 and future respiratory pandemics.Keywords
This publication has 32 references indexed in Scilit:
- Iron and iron-related proteins in COVID-19Clinical and Experimental Medicine, 2022
- The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality careEuropean Journal of Medical Genetics, 2022
- An alternative way to perform diagnostic nasopharyngeal swab for SARS-CoV-2 infectionAmerican Journal of Otolaryngology, 2021
- Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19Angiogenesis, 2020
- Hereditary Hemorrhagic Telangiectasia2019
- The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasiaThe Laryngoscope, 2015
- The effects of epistaxis on health‐related quality of life in patients with hereditary hemorrhagic telangiectasiaInternational Forum of Allergy & Rhinology, 2014
- Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: A population based studyAmerican Journal of Medical Genetics Part A, 2012
- An epistaxis severity score for hereditary hemorrhagic telangiectasiaThe Laryngoscope, 2010
- Health-related quality of life in a rare disease: Hereditary hemorrhagic telangiectasia (HHT) or Rendu?Osler?Weber DiseaseQuality of Life Research, 2004